v3.26.1
Segment and Geographic Information - Segment Reporting (Details) - USD ($)
$ in Millions
12 Months Ended
Apr. 24, 2026
Apr. 25, 2025
Apr. 26, 2024
Segment Reporting [Line Items]      
Net sales $ 36,364 $ 33,537 $ 32,364
Cost of products sold, excluding amortization of intangible assets 12,721 11,632 11,216
Research and development expense 2,873 2,732 2,735
Selling, general, and administrative expense 11,784 10,849 10,736
Reportable segment operating profit 6,467 5,955 5,144
Currency and other (57) (309) (123)
Other non-operating expense (income), net 384 402 412
Amortization of intangible assets (1,772) (1,807) (1,693)
Certain litigation charges, net (113) (317) (149)
Income before income taxes 6,136 5,628 4,837
Operating Segments      
Segment Reporting [Line Items]      
Net sales 33,079 30,734 29,654
Cost of products sold, excluding amortization of intangible assets 11,323 10,287 9,819
Research and development expense 2,438 2,298 2,261
Selling, general, and administrative expense 10,451 9,695 9,470
Other segment items 4 8 11
Reportable segment operating profit 8,862 8,447 8,093
Segment reconciling items      
Segment Reporting [Line Items]      
Currency and other (112) (14) 81
Interest expense, net (715) (729) (719)
Other non-operating expense (income), net 384 402 412
Amortization of intangible assets (1,772) (1,807) (1,693)
Restructuring and associated costs (370) (303) (389)
Acquisition and divestiture-related items (173) (124) (777)
Certain litigation charges, net (113) (317) (149)
Medical device regulations   (52) (119)
Other adjustments 39 (90)  
Cardiovascular | Operating Segments      
Segment Reporting [Line Items]      
Net sales 13,976 12,481 11,831
Cost of products sold, excluding amortization of intangible assets 4,695 4,136 3,890
Research and development expense 1,136 1,020 991
Selling, general, and administrative expense 4,519 4,021 3,901
Other segment items (46) (41) (28)
Reportable segment operating profit 3,672 3,344 3,078
Neuroscience | Operating Segments      
Segment Reporting [Line Items]      
Net sales 10,287 9,846 9,406
Cost of products sold, excluding amortization of intangible assets 3,151 2,896 2,761
Research and development expense 616 612 624
Selling, general, and administrative expense 3,421 3,275 3,169
Other segment items 36 31 30
Reportable segment operating profit 3,062 3,031 2,822
Medical Surgical | Operating Segments      
Segment Reporting [Line Items]      
Net sales 8,815 8,407 8,417
Cost of products sold, excluding amortization of intangible assets 3,476 3,255 3,168
Research and development expense 686 665 646
Selling, general, and administrative expense 2,511 2,398 2,400
Other segment items 14 18 9
Reportable segment operating profit 2,128 2,071 2,193
Other Operating Segments, Including Diabetes | Operating Segments      
Segment Reporting [Line Items]      
Net sales 3,247 2,892 2,710
Reportable segment operating profit 106 214 $ 96
Other Operating Segments | Operating Segments      
Segment Reporting [Line Items]      
Other adjustments $ 39 $ (90)